Axial spondyloarthritis (axSpA) is a spectrum of painful inflammatory axial disease.

axSpA can be considered as a spectrum of disease consisting of non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS).1

Diagram showing axSpA leading to nr-axSpA and AS

At least 50% of patients are likely to progress from nr-axSpA to AS in their lifetime.2

Risk factors for progression include:2

 

Hand drawn icon of positive symbol

HLA-B27 positive

Hand drawn icon of high inflammatory activity

High inflammatory activity

  Elevated CRP

  Inflammatory changes in sacroiliac joints on MRI

Hand drawn icon showing buttock pain

Buttock pain

 

 
Hand drawn icon of smoking cigarette

Smoking

Hand drawn icon of previous uveitis eye

Previous uveitis

Hand drawn icon showing low-grade sacroiliitis

Low-grade sacroiliitis

 

 

Image of blue arrow with link to Disease Burden

 

AS, ankylosing spondylitis; axSpA, axial spondyloarthritis; CRP, C-reactive protein; HLA-B27, human leukocyte antigen B27; MRI, magnetic resonance imaging; nr-axSpA; non-radiographic axial spondyloarthritis.

References:

  1. Rudwaleit M, et al. Ann Rheum Dis. 2009;68(6):777–783.
  2. Protopopov M & Poddubnyy D. Expert Rev Clin Immunol. 2018;14(6):525–533.
Rate this content: 
No votes yet
UK | April 2021 | 114833
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]